(Reuters) – Moderna Inc plans to price its experimental coronavirus vaccine in a way that ensures broad access, it said on Wednesday, adding that it did not intend to conduct late-stage trials of the shot outside the United States.
Chief Executive Officer Stphane Bancel declined to comment on the specific price of the vaccine on a conference call with analysts.
The Financial Times reported on Tuesday, citing unnamed sources, that the company was planning to price the vaccine at $50 to $60 per course, at least $11 more than another vaccine from Pfizer Inc and BioNTech.
(Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty)
